DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer

Information source: Henry M. Jackson Foundation for the Advancement of Military Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Ovarian Cancer; Primary Peritoneal Cancer

Intervention: imatinib mesylate by mouth (Drug); Gemcitabine Intravenous (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: Henry M. Jackson Foundation for the Advancement of Military Medicine

Official(s) and/or principal investigator(s):
David McCune, MD, MPH, Principal Investigator, Affiliation: Madigan Army Medical Center


This study will evaluate the efficacy and tolerability of the combination of Gleevec and Gemzar in patients with ovarian cancer, who have progressed after receiving at least one prior chemotherapy treatment. Gleevec is an oral chemotherapy drug used is this study and Gemzar is an IV chemotherapy drug used. Participation in the treatment portion of the study will continue as long as the patient's tumors shrink or remain stable and as long as the patient is able to tolerate the study drug. The follow-up portion of the study will last for 5 years.

Clinical Details

Official title: A Phase II Trial of Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer Who Have Failed at Least Two Prior Therapies

Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

The Cystostatic, Anti-tumor Activity of the Combination of Gleevec and Gemzar Via Progression-free Survival for at Least Six Months in Patients With Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma.

To Determine the Safety and Tolerability Via Frequency and Severity of Adverse Effect of Combination Gleevec and Gemzar in This Cohort of Patients as Assessed Byt Common Toxicity Criteria

Secondary outcome:

Tumor Response Rates Using Modified SWOG Criteria to the Combination of Gleevec and Gemzar in Patients With Relapsed Ovarian Cancer Who Have Failed at Least One Prior Chemotherapy Treatment.

To Determine the Distribution of the Overall Survival

To Estimate the Clinical Response Rate(Partial and Complete Response as Defined Under the SWOG Criterial)

To Assess the Effects of Prognostic Variables; Initial Performance Status; Platinum Sensitivity, and Mucinous (or Clear Cell)Histology on Progression-free Survival Overall.

Detailed description: Each 21 day period will be considered a cycle. Disease status will be assessed with a Cancer Antigen (CA)-125 prior to the start of each new cycle with an assessment of measurable diseased by either CT or MRI every 6 weeks. Treatment will continue until disease progression, unacceptable toxicities, or the patient elects to withdraw from the study. All patients will be followed until disease progression or study withdraw. In addition, following disease progression, patients will be monitored for delayed toxicity and survival for a period of 5 years, unless consent is withdrawn.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Female.


Inclusion Criteria:

- Patients 18 years of age or greater

- Histologically documented diagnosis of ovarian cancer or primary peritoneal cancer.

Histological subtypes include: mucinous tumor, serous tumor, endometrioid tumor, and other histologies including clear cell and undifferentiated epithelial tumors.

- At least one measurable site of disease (as defined by Southwestern Oncology Group

Solid Tumor Response Criteria) or other response assessment criteria, as appropriate.

- Patients must have relapsed after receiving at least one prior platinum-based


- Performance status of 0, 1, 2, (ECOG)

- Adequate end organ function: Total bilirubin < 1. 5 x ULN, SGOT and SGPT < 2. 5 UNL,

creatinine < 1. 5 x UNL, ANC > 1. 5 x 109/L, platelets > 100 x 109/L.

- Patients will most likely have had their ovaries removed at the time off initial

surgery. If any subjects are of childbearing potential at the time of entry, they must have negative pregnancy test within 7 days before initiation of study drug dosing. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Subjects of reproductive potential must agree to employ and effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of the study drug.

- Written, voluntary informed consent.

- Patients must be eligible for care at a military medical treatment facility.

Exclusion Criteria:

- Patient has received prior treatment with Gemzar.

- Patient has received any other investigational agents within 28 days of the first day

of study drug dosing.

- Patient is < 5 years free of another primary malignancy except: if the other primary

malignancy is neither currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed.

- Patient with Grade III/IV cardiac problems as defined but the New York Heart

Association Criteria.

- Patients who are pregnant or breast-feeding.

- Patient has a severe and/or uncontrolled medical disease (i,e. uncontrolled diabetes,

uncontrolled chronic renal disease, or active uncontrolled infection).

- Patient has a known untreated or progressive brain metastasis.

- Patient has known chronic liver diseases (i. e. chronic active hepatitis, and


- Patient has a known diagnosis of human immunodeficiency virus (HIV infection ).

- Patient received chemotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin-C)

prior to study entry, unless the disease is rapidly progressing..

- Patient previously received radiotherapy to greater than or equal to 25% of the bone


- Patient had a major surgery within 2 weeks prior to study entry.

- Patient with any significant history of non-compliance to medical regimens or with

inability to grant reliable informed consent.

Locations and Contacts

Madigan Army Medical Center, Tacoma, Washington 98431, United States
Additional Information

Starting date: June 2009
Last updated: October 20, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017